Within the past few years, an expanding collection of epigenetic modulators – spanning multiple classes and disease implications – have been positioned as promising targets for therapeutic development. Since the approval of first-generation epigenetic therapies, an increasing amount of chemically tractable epigenetic targets, such as Histone Deacetylases (HDACs), Histone Methyltransferases (HMTs), Histone Demethylases (HDMs), and a distinct set of chromatin readers – the BET family bromodomains – have given rise to novel inhibitors that are now in preclinical and clinical development. However, obtaining potent, highly-selective and cell-active inhibitors requires skillful utilization of varied assays and screening methods, such as high-throughput screening (HTS), focused screening, knowledge/fragment-based approaches, and phenotypic assays to efficiently navigate lead discovery of epigenetic targets. Cambridge Healthtech Institute is proud to announce the inaugural Epigenetic Inhibitor Discovery conference, gathering a diverse cross-section of academic and industry leaders actively working on developing epigenetic inhibitors.
Get Free Registration
Help us cover this conference, and we’ll set you up with a complimentary registration. All you have to do is be willing to show up and write up a quick report. Click below to let us know you’re interested.